title: Indirect costs of respiratory syncytial virus hospitalizations: a commentary.
authors.affiliation: Analytics & Outcomes Research, Caremark, Inc.
authors.forename: Andrea S
authors.initials: AS
authors.lastname: Marks
mesh_terms: D003362:Cost-Benefit Analysis; D003627:Data Interpretation, Statistical; D017721:Hospital Costs; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008329:Managed Care Programs; D018357:Respiratory Syncytial Virus Infections / Q000191:economics* / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000191:economics; D012307:Risk Factors
chemical_list: D022261:Respiratory Syncytial Virus Vaccines